A77 1726 increases IL-1 receptor antagonist (IL-1Ra) secretion in human synovial fibroblasts and articular chondrocytes in the presence of tumour necrosis factor (TNF)-α
2011-12-31T04:37:28Z (GMT) by
<p><b>Copyright information:</b></p><p>Taken from "The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes"</p><p>Arthritis Research & Therapy 2004;6(3):R181-R189.</p><p>Published online 19 Feb 2004</p><p>PMCID:PMC416438.</p><p>Copyright © 2004 Palmer et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</p> Human osteoarthritis (OA) synovial fibroblasts (passage 2) and de-differentiated human OA articular chondrocytes (passage 7) were stimulated (closed symbols) or not (open symbols) with 10 ng/ml TNF-α alone or in combination with 50 μmol/l or 100 μmol/l A77 1726 for 48 hours. A77 1726 was added 2 hours before stimulation with TNF-α. IL-1Ra concentrations in culture supernatants were measured by ELISA. Results are represented as means ± SEM of three determinations in a representative experiment. A similar dose dependency was observed in cells obtained from three different donors (three OA samples) for synovial fibroblasts and three different donors (three OA samples) for de-differentiated chondrocytes. *< 0.001 versus control; < 0.001 versus TNF-α alone.